Effects of FLAG regimen in treatment of refractory or relapsed acute myeloid leukemia.
- Author:
Xiao-Xiong WU
1
;
Wan-Ming DA
;
Hong-Hua LI
;
Yu ZHAO
;
Quan-Shun WANG
;
Shu-Hong WANG
;
Hai-Yan ZHU
Author Information
1. Department of Hematology, General Hospital of Chinese PLA, Beijing 100853, China. wuxx1963@163.com
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Antineoplastic Combined Chemotherapy Protocols;
adverse effects;
therapeutic use;
Cytarabine;
administration & dosage;
adverse effects;
Diarrhea;
chemically induced;
Drug Resistance, Neoplasm;
Female;
Granulocyte Colony-Stimulating Factor;
administration & dosage;
adverse effects;
Humans;
Leukemia, Monocytic, Acute;
drug therapy;
pathology;
Leukemia, Myeloid, Acute;
drug therapy;
pathology;
Leukemia, Myelomonocytic, Acute;
drug therapy;
pathology;
Male;
Middle Aged;
Nausea;
chemically induced;
Neoplasm Recurrence, Local;
Respiratory Tract Infections;
chemically induced;
Treatment Outcome;
Vidarabine;
administration & dosage;
adverse effects;
analogs & derivatives
- From:
Journal of Experimental Hematology
2005;13(3):394-396
- CountryChina
- Language:Chinese
-
Abstract:
In order to evaluate the effects of FLAG regimen in treatment of refractory and relapsed acute myeloid leukemia (AML), 27 patients with refractory or relapsed acute myeloid leukemia (10 refractory AML patients, 17 relapsed AML patients) were treated with FLAG regimen. The results show that the rate of complete remission was 48.2% (13/27), the rate of partial remission was 14.8% (4/27), and the overall response rate was 63.0%. Main toxicities were gastrointestinal side effectes, myelosupression and neutropenia. It is concluded that FLAG regimen can be employed in treatment of the refractory or relapsed patients who were not respond to other regimen, and the regiment was safe.
